Literature DB >> 26084262

Chronic arterial hypertension impedes glioma growth: a multiparametric MRI study in the rat.

Annelise Letourneur1,2,3,4, Simon Roussel1,2,3,4, Myriam Bernaudin1,2,3,4, Fabien Fillesoye1,2,3,4, Jérôme Toutain1,2,3,4, Eric T MacKenzie1,2,3,4, Edwige Petit1,2,3,4, Omar Touzani1,2,3,4, Samuel Valable1,2,3,4.   

Abstract

Glioblastoma is the most aggressive brain tumor and is almost always fatal. These tumors are highly vascularized and angiogenesis is one of the pre-eminent mechanisms underlying their growth. Chronic arterial hypertension (CAH) is a common and worldwide pathology that markedlly alters the structure and function of the vasculature. Yet, essential hypertension is associated in the brain with potential locally impaired vasoreactivity, disturbed perfusion supply and hypoxia phenomena. Even though CAH is a global burden and has an important impact on brain function, nothing is known about the way this frequent pathology would interact with the evolution of glioma. We sought to determine if arterial hypertension influences gliobastoma growth. In the present study, rat glioma C6 tumor cells were implanted in the caudate-putamen of spontaneously hypertensive rats (SHR) or their normotensive controls, the Wistar-Kyoto (WKY) rats. The evolution of the tumor was sequentially analyzed by multiparametric magnetic resonance imaging and the inflammatory response was examined by histochemistry. We found that CAH significantly attenuates the growth of the tumor as, at 21 days, the volume of the tumor was 85.4±34.7 and 126.1±28.8 mm(3), respectively, in hypertensive and normotensive rats (P<0.02). Moreover, cerebral blood volume and cerebral blood flow were greater in the tumors of hypertensive rats (P<0.05). The lesser growth of the tumor observed in normotensive animals was not due to an enhanced rejection of the tumor cells in WKY rats, the inflammatory response being similar in both groups. For the first time, these results show that CAH impedes the growth of glioblastoma and illustrate the need to further study the impact of hypertension on the evolution of brain tumors.

Entities:  

Mesh:

Year:  2015        PMID: 26084262     DOI: 10.1038/hr.2015.66

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  64 in total

1.  Use of dynamic susceptibility-contrast MRI (DSC-MRI) to assess perfusion changes in the ipsilateral brain parenchyma from glioblastoma.

Authors:  Stephan Ulmer; Carsten Liess; Santosh Kesari; Nadine Otto; Torsten Straube; Olav Jansen
Journal:  J Neurooncol       Date:  2008-09-21       Impact factor: 4.130

Review 2.  Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature.

Authors:  Giuseppe Lombardi; Fable Zustovich; Patrizia Farina; Pasquale Fiduccia; Alessandro Della Puppa; Valentina Polo; Roberta Bertorelle; Marina P Gardiman; Alberto Banzato; Pietro Ciccarino; Luca Denaro; Vittorina Zagonel
Journal:  Anticancer Drugs       Date:  2013-01       Impact factor: 2.248

Review 3.  Recent advances in therapy for glioblastoma.

Authors:  Jennifer Clarke; Nicholas Butowski; Susan Chang
Journal:  Arch Neurol       Date:  2010-03

4.  Global burden of hypertension: analysis of worldwide data.

Authors:  Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He
Journal:  Lancet       Date:  2005 Jan 15-21       Impact factor: 79.321

Review 5.  Cerebral autoregulation.

Authors:  O B Paulson; S Strandgaard; L Edvinsson
Journal:  Cerebrovasc Brain Metab Rev       Date:  1990

Review 6.  Standard therapy for glioblastoma--a review of where we are.

Authors:  Ryo Nishikawa
Journal:  Neurol Med Chir (Tokyo)       Date:  2010       Impact factor: 1.742

Review 7.  Remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment.

Authors:  Ernesto L Schiffrin
Journal:  Am J Hypertens       Date:  2004-12       Impact factor: 2.689

8.  The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer.

Authors:  A Bamias; E Manios; A Karadimou; F Michas; G Lainakis; C Constantinidis; C Deliveliotis; N Zakopoulos; M A Dimopoulos
Journal:  Eur J Cancer       Date:  2011-05-04       Impact factor: 9.162

9.  In vivo MRI tracking of exogenous monocytes/macrophages targeting brain tumors in a rat model of glioma.

Authors:  Samuel Valable; Emmanuel L Barbier; Myriam Bernaudin; Simon Roussel; Christoph Segebarth; Edwige Petit; Chantal Rémy
Journal:  Neuroimage       Date:  2008-04-01       Impact factor: 6.556

10.  Effect of β-blockers and other antihypertensive drugs on the risk of melanoma recurrence and death.

Authors:  Vincenzo De Giorgi; Sara Gandini; Marta Grazzini; Silvia Benemei; Niccolò Marchionni; Pierangelo Geppetti
Journal:  Mayo Clin Proc       Date:  2013-11       Impact factor: 7.616

View more
  2 in total

1.  Does chronic hypertension prevent cancer progression?

Authors:  Masaki Mogi; Masatsugu Horiuchi
Journal:  Hypertens Res       Date:  2015-07-23       Impact factor: 3.872

2.  Associations between prediagnostic blood glucose levels, diabetes, and glioma.

Authors:  Judith Schwartzbaum; Michael Edlinger; Victoria Zigmont; Pär Stattin; Grzegorz A Rempala; Gabriele Nagel; Niklas Hammar; Hanno Ulmer; Bernhard Föger; Göran Walldius; Jonas Manjer; Håkan Malmström; Maria Feychting
Journal:  Sci Rep       Date:  2017-05-03       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.